Now with a richer pipeline of biological and
pharmaceutical products, Pfizer Animal Health will expand its worldwide
leadership role in animal health research focused on meeting unmet needs in
veterinary care.
Pfizer invests an estimated $300 million annually in veterinary R&D from
major, global centers in Australia, Belgium, India, Spain, the United Kingdom,
and the United States.
Pfizer Animal Health also is building a diverse and innovative portfolio in
biopharmaceutics, and emerging diseases. To help find new medicines for animals,
hundreds of Pfizer Animal Health researchers in veterinary medicine leverage the
work of thousands of Pfizer scientists searching for new human health solutions
A Business Development &
Global Alliances
team of medical, scientific and business experts collaborate with external R&D
partners, explore new market opportunities, technology or product acquisitions –
all in the pursuit of innovation in veterinary medicine.
Areas of R&D Focus |
Livestock
- Antimicrobials
- Antiparasitics
- Growth and production enhancement
- Metabolic Disease
- Respiratory and reproductive vaccines
- Food Safety vaccines
- Mastitis vaccines
- Enteric vaccines
- Parasitic vaccines
|
Companion Animals
- Antimicrobials
- Antiparasitics
- Pain and Inflammation
- Metabolic Disease
- Cancer
- Skin diseases/allergies
- Infectious disease and parasitic vaccines
- Internal medicine
- Enteric vaccines
|
|
|